The purpose of this study is to evaluate the efficacy, safety, and tolerability of povetacicept in participants with primary membranous nephropathy (pMN).
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
176
Solution for Subcutaneous Injection.
Capsules for Oral Administration.
Proportion of Participants with Complete Clinical Remission Definition 1 (CR1)
Time frame: At Week 104
Proportion of Participants with Complete Clinical Remission Definition 2 (CR2)
Time frame: At Week 104
Proportion of Participants with Overall Clinical Remission (OR)
Time frame: At Week 104
Safety and Tolerability as Assessed by Number of Participants With Adverse events (AEs) and Serious Adverse Events (SAEs)
Time frame: From Day 1 up to Week 112
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Renal Associates
Montgomery, Alabama, United States
RECRUITINGSouthwest Kidney Institute, PLC (SKI) - Surprise
Surprise, Arizona, United States
RECRUITINGAcademic Medical Research Institute (AMRI)
Los Angeles, California, United States
RECRUITINGValiance Clinical Research - Internal Medicine
Tarzana, California, United States
RECRUITINGWestern Nephrology & Metabolic Bone Disease PC
Arvada, Colorado, United States
RECRUITINGBioresearch Partner
Miami, Florida, United States
RECRUITINGCTR Oakwater, LLC
Orlando, Florida, United States
RECRUITINGClinical Site Partners, LLC - Orlando
Winter Park, Florida, United States
RECRUITINGDaVita Clinical Research Columbus
Columbus, Georgia, United States
RECRUITINGGeorgia Nephrology
Lawrenceville, Georgia, United States
RECRUITING...and 88 more locations